The biological role of SIRT6 in HCC chemosensitivity is consistent with previous studies that SIRT6 depletion or inhibitor enhanced chemosensitivity (Liu et al., 2013; Sociali et al., 2015) in prostate cancer and breast cancer, respectively. Here, SIRT6 is linked to prostate cancer.